



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Glenoid Failure after Total Shoulder Arthroplasty, cemented all-polyethylene versus metal-backed: A Systematic Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043449
Article Type:	Protocol
Date Submitted by the Author:	03-Aug-2020
Complete List of Authors:	Zan, Renato Aroca; Universidade Federal de Sao Paulo, Orthopedics and Traumatology - Division of Hand surgery and Upper Limb Lazarini, Rafael; Hospital Felicio Rocho, Department of Orthopaedics and Traumatology Matsunaga, Fabio; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb Netto, Nicola; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb Belloti, João ; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb; Universidade Federal de Sao Paulo Escola Paulista de Medicina, Tamaoki, Marcel Jun; Universidade Federal de Sao Paulo, Orthopaedics
Keywords:	Shoulder < ORTHOPAEDIC & TRAUMA SURGERY, STATISTICS & RESEARCH METHODS, Adult orthopaedics < ORTHOPAEDIC & TRAUMA SURGERY, Elbow & shoulder < ORTHOPAEDIC & TRAUMA SURGERY, RADIOLOGY & IMAGING

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# **Glenoid Failure after Total Shoulder Arthroplasty, cemented all-polyethylene versus metal-backed: A Systematic Review Protocol**

**Authors:** Renato Aroca Zan ([re\\_zan@hotmail.com](mailto:re_zan@hotmail.com)), Rafael Fuchs Lazarini ([fuchslazarini@yahoo.com.br](mailto:fuchslazarini@yahoo.com.br)), Fabio Teruo Matsunaga ([fteruo@gmail.com](mailto:fteruo@gmail.com)), Nicola Archetti Netto ([narchetti@uol.com.br](mailto:narchetti@uol.com.br)), João Carlos Belloti ([jcbelloti@gmail.com](mailto:jcbelloti@gmail.com)) & Marcel Jun Sugawara Tamaoki ([marceltamaoki@gmail.com](mailto:marceltamaoki@gmail.com))

## **Abstract**

## **Introduction**

Anatomical Total Shoulder Arthroplasty (TSA) is an effective treatment adopted in patients with glenohumeral osteoarthritis. The glenoid component failure is the main risk that occurs in this therapeutic choice; however, doubts remain, regarding the selection of the best implant in order to avoid such complication.

## **Methods and analysis**

A systematic review of randomised clinical trials (RCTs) or quasi-randomised trials will be carried out, applying the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols,

comparing polyethylene (keeled and pegged) versus metal back implants in adult patients with glenohumeral osteoarthritis.

Our search strategy will be carried out in the MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, Web of Science. Data management and extraction will be performed using a data withdrawal form and by analysing study method characteristics, participant characteristics, intervention characteristics, results, methodological domains.

The summaries of research evidence will be accessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Shoulder function through functional scores such as Constant-Murley (CM) and American Shoulder and Elbow Surgeons (ASES), pain (Visual Analogue Scale), infection, procedure failure, radiograph radiolucency and loosening, are the selected outcomes. Another analysis such as subgroup, heterogeneity, sensitivity and statistical are going to be performed whenever possible.

**Discussion**

This systematic review aims to analyse how glenoidal implants behave in Total Shoulder Arthroplasties and therefore provide evidence concerning the best clinical practice in order to avoid complications.

**Ethics and dissemination:**

1  
2  
3 41 This study has been approved by the IRB of Universidade Federal de São  
4  
5  
6 42 Paulo (protocols 0725/2017, 2.157.415 and 70473017.5.0000.5505) and  
7  
8  
9 43 findings will be disseminated through peer-reviewed publication and  
10  
11 44 conference presentations.  
12

### 13 14 45 **Systematic review registration**

15  
16 46 PROSPERO, CRD 42018079537.  
17

### 18 19 47 **Keywords**

20  
21  
22 48 Shoulder, arthroplasty, glenoid, loosening, keel, peg, metal back,  
23  
24 49 osteoarthritis, replacement.  
25  
26  
27

### 28 29 50 **Strengths and limitations of this study**

- 30  
31  
32  
33 51 • This systematic review is a response to priority setting conducted in  
34  
35 52 collaboration with policy-makers who recognised a gap in available  
36  
37 53 synthesised evidence regarding approaches for hypertension  
38  
39 54 screening (mass, opportunities or targeted screening strategies).  
40  
41  
42  
43  
44 55 • This review will include randomised and non-randomised controlled  
45  
46 56 studies to capture all relevant evidence regarding programmes of  
47  
48 57 hypertension screening.  
49  
50  
51  
52  
53 58 • We will conduct a comprehensive search across several databases  
54  
55 59 without restricting for language or publication status.  
56  
57  
58  
59  
60

- We plan to meta-analyse outcome data; however, included studies may vary in terms of study design and the outcomes reported, and therefore we may present narrative evidence syntheses.
- The review authors have complementary expertise in systematic review methods and content which will ensure a review that is relevant for policy and practice.

**Introduction**

Osteoarthritis (OA) of the glenohumeral joint is a common clinical condition that affects adult population [1]., mainly in patients between 60 and 80 years old [2].

Total Shoulder Arthroplasty has been proved to be effective to treat this condition [3]. There has been an increase rate in these procedures between 300% to 400% for the last two decades (1990-2010), varying from 13.000 to 42.000 approximately, with an annual variation in the order of 10.6% [4,5]. It was also observed that approximately 24% of complications of this surgery were related to glenoid implant and 28.5% of those required surgical revision due to loosening. Loosening of the glenoid implant is the main cause of failure, followed by pain and decrease in range of motion after a TSA [6,7,8,9]. This important complication compromises the function of the joint and can even lead need of reoperation.

1  
2  
3 80 This systematic review aims to evaluate the glenoid component by  
4  
5  
6 81 comparing the effectiveness of different types of implants, either with  
7  
8  
9 82 metal back or those exclusive in polyethylene (keeled or pegged),  
10  
11 83 considering function of the shoulder and complications (persistence or  
12  
13  
14 84 worsening of pain, infection and failure of the surgery regarding glenoidal  
15  
16  
17 85 implants loosening in the glenohumeral joint).

## 18 19 86 **Methods and analysis**

### 20 21 87 **Types of Studies and inclusion criteria:**

22  
23 88 This systematic review will follow recommendations proposed by the  
24  
25  
26 89 Cochrane Handbook of Interventions Reviews [10,11] and PRISMA  
27  
28  
29 90 protocols [12,13]. Our study will include only randomised or quasi-  
30  
31  
32 91 randomised controlled clinical trials, comparing metal-backed glenoid  
33  
34  
35 92 designs and polyethylene (keeled or pegged) design in Total Shoulder  
36  
37  
38 93 Arthroplasties.

### 39 40 94 **Ethics Approval and dissemination:**

41  
42 95 This study has been approved by the Institutional Review Board (IRB) of  
43  
44  
45 96 Universidade Federal de São Paulo (protocol 0725/2017, 2.157.415 and  
46  
47  
48 97 70473017.5.0000.5505) (document attached).

### 49 50 98 **Types of participants (inclusion and exclusion criteria):**

51  
52 99 The inclusion eligibility studies that assessed adults that underwent TSA  
53  
54  
55 100 due to idiopathic and inflammatory OA [14,15,16,17]. The following  
56  
57  
58 101 exclusion criteria were adopted: Patients with previous surgery,  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

102 neurological diseases (Charcot's Arthropathy, Parkinson's disease),

103 Revision surgeries of arthroplasty and Reverse Total Arthroplasty.

104 **Primary Outcomes:**

105 Functional results, complications and failure represented by new surgical

106 intervention, will be our main outcomes. We will consider the Constant-

107 Murley (CM) [18], American Shoulder and Elbow Surgeons (ASES) [19]

108 and University of California at Los Angeles (UCLA) [20] to measure

109 function as a validated score. Complications like deep infection affecting

110 prosthesis components, persistence or worsening of pain (Visual Analogue

111 Scale - VAS) [21], loosening or breakage of implanted materials,

112 dislocation, surgical revision.

113 **Secondary Outcomes:**

114 Clinical and radiographic outcomes will be assessed by range of motion

115 (forward flexion, lateral and internal rotation) and indirect radiographic

116 signs that evidence the loosening of the glenoid implant. The Lazarus

117 classification for keeled components and Franklin classification for pegged

118 components were the systems selected to assess radiolucency concerning

119 those all-polyethylene components [22,23].

120 Quality of life analysis validated short form scores 36 [24], will also be

121 assessed.

122 **Search methods and strategy:**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool

1  
2  
3 123 The electronic search will be carried out in the MEDLINE (PubMed),  
4  
5  
6 124 Cochrane Central Register of Controlled Trials [25,26], EMBASE, Web of  
7  
8  
9 125 Science, International Clinical Trials Registry Platform, ClinicalTrials.gov  
10  
11 126 and Literatura Latino-Americana e do Caribe em Ciências da Saúde  
12  
13  
14 127 (LILACS for randomised or quasi-randomised RCTs). The grey literature  
15  
16  
17 128 will also be searched through Google Scholar, OpenGrey and GreyNet  
18  
19  
20 129 [27].

21  
22 130 We are going to use the following terms in different combinations and  
23  
24  
25 131 combinations for our search: “total shoulder arthroplasty”, “glenoid”,  
26  
27  
28 132 “keeled”, “pegged”, “loosening”, “metal-backed” and “radiolucency”. No  
29  
30  
31 133 restriction on language or publication status.

#### 32 33 134 **Data collection and analysis:**

34  
35 135 Two independent reviewers will access the selected studies, as well as the  
36  
37  
38 136 data extracted from these studies using EndNote X9, in order to facilitate  
39  
40  
41 137 collaboration among them during the selection process.

42  
43 138 Two authors will select independently and analyse the eligible studies for  
44  
45  
46 139 this systematic review through the title and abstract. The selected studies  
47  
48  
49 140 will be entirely reviewed. Any disagreement will be resolved through  
50  
51  
52 141 discussion and, when necessary, will be judged by a third author in an  
53  
54  
55 142 attempt to resolve a possible conflict.

#### 56 57 143 **Data Extraction and Handling:**

58  
59  
60

1  
2  
3 144 Data extraction will be performed by two reviewers will extract the data  
4  
5  
6 145 using an appropriate extraction form based on methodological  
7  
8  
9 146 characteristics, including design and duration, whether the protocol was  
10  
11 147 published prior the recruitment of the patients, possible funding sources  
12  
13  
14 148 and study registration; characteristics of the participants including location,  
15  
16 149 number of recruits, their evaluation, inclusion and exclusion criteria, age  
17  
18  
19 150 and classification relevant to the disease addressed; characteristics of the  
20  
21  
22 151 intervention like duration, surgery type and complications; results through  
23  
24  
25 152 time and loss of follow-up; methodological domains and risk of bias.  
26  
27  
28 153 The extracted data will be also classified according to the time of follow-up  
29  
30 154 into early and late, establishing 1 year as the cut off for this division.

31  
32  
33 155 **Access to risk of bias:**

34  
35 156 Two authors will independently evaluate various aspects of methodological  
36  
37  
38 157 quality of the included studies using a modified version of the Cochrane  
39  
40  
41 158 Bone Joint and Muscle Trauma Group tool form [28]. Some items will be  
42  
43  
44 159 considered: random sequence generation, allocation concealment,  
45  
46 160 participant blinding, outcome assessment blinding, selective reporting and  
47  
48  
49 161 potential influence of incomplete outcome data, in each trial, will also be  
50  
51  
52 162 carried out. After judgment and classification, these criteria will produce  
53  
54 163 three levels of bias: low, high or unclear. Disagreements will be solved by  
55  
56  
57 164 the analysis of a third reviewer [29,30].

58  
59 165 **Measures of treatment effect:**  
60

166 The resulting dichotomous data will be analysed with relative risk (RR)  
167 with a 95% confidence interval. When appropriate, we will express the  
168 estimated effects as numbers that need treatment (NNTs). Data on  
169 continuous outcomes will be expressed as an average difference of 95% in  
170 the confidence interval (CI). We intend to group the results with the mean  
171 difference (MD) if two or more trials reveal results from the same valid  
172 instrument of evolution (with the same units of measurement). If primary  
173 studies measure the same variables using different instruments (as well as  
174 different units of measurement), Cochrane Review Manager on its 5.3  
175 version will be used for the statistical analyse.

#### 176 **Dealing with Missing Data:**

177 We will perform an intention-to-treat analysis in order to include all  
178 randomised participants of any intervention. Insufficient information  
179 according to the estimated effects, as well as the number of participants,  
180 mean, uncertainty measurement (standard deviation or error) or number of  
181 events; we will contact the authors of the selected trials.

182 An analysis will be carried out independently of the lost data, submitting  
183 them to the worst and best scenarios.

#### 184 **Heterogeneity Analysis:**

185 The heterogeneity of the estimated effects between the included studies  
186 will be evaluated through visual inspection of the forest plots and the  
187 statistical  $I^2$  test (significant > 50%).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

188     **Data Synthesis:**

189     The results of comparable tests will be grouped using the fixed-effect  
190     model and a 95% CI. However, the variable model will be used when there  
191     is a diversity in clinical or methodological characteristics.

192     **Subgroup Analysis and Heterogeneity Investigation:**

193     Where appropriate, subgroups will be analysed in order to explore the  
194     difference in side effect related to the type of glenoid selected.

195     **Confidence in Cumulative Evidence:**

196     We will apply GRADE ([www.gradepro.org](http://www.gradepro.org)) in order to describe and rate  
197     the quality of evidence and the strength of the recommendations,  
198     classifying them as *high*, *moderate*, *low* and *very low* [31,32,33].

199     **Results:**

200     Following this protocol publication, electronic searches will be carried out  
201     and the selected trials will be analysed. By the time we get the final results,  
202     we are going to send this paper for publication. Our intention is to have it  
203     ready by the end of 2021.

204     **Discussion:**

205     We observe an increasing rate of TSA in the adult population and,  
206     therefore, complications also assume an increasingly important role in this  
207     particular treatment. The glenoid component is the main site of these  
208     complications in terms of pain, limiting range of motion, but also in

worsening quality of life. These findings are correlated with loosening or even implant breakage [34]. There are some evidences that cemented all-polyethylene glenoid implant has a better loosening rate compared to the metal-backed design, but in terms of radiolucency, this statement is reversed [35,36,37,38].

Nowadays we have several types of glenoid implants in both polyethylene and metal-backed designs, however searching the literature, there is a lack of systematic reviews. In fact, we found only one study including trials with low level of evidence such as nonrandomised and case series [39].

Further evaluation on this subject with better methodological quality should be carried out covering functional, clinical, and radiographic outcomes as well as complications.

We expect difficulty to find trials with adequate sample size, standardization in the functional scores, follow-up pattern and also methods of the results, promoting a possible limitation in our revision. The aim of this study is to provide support and scientific evidence for decision making in orthopaedic clinical practice regarding the glenoid implant selection on TSA, serving as a guide for future trials with better methodological quality.

## **List of abbreviations:**

**(ASES)**American Shoulder and Elbow Surgeons

**(CI)**Confidence Interval

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 230    **(CM)** Constant-Murley
- 231    **(GRADE)** Grading of Recommendations Assessment, Development and
- 232    Evaluation
- 233    **(LILACS)**Literatura Latino-Americana e do Caribe em Ciências da
- 234    Saúde
- 235    **(MD)** Mean Difference
- 236    **(NNTs)** Numbers that Need Treatment
- 237    **(OA)** Osteoarthritis
- 238    **(PRISMA)** Preferred Reporting Items for Systematic Review and Meta-
- 239    Analysis
- 240    **(RCTs)** Randomised Clinical Trials
- 241    **(RR)** Relative Risk
- 242    **(SMD)** Standard Mean Difference
- 243    **(TSA)** Total Shoulder Arthroplasty
- 244    **(UCLA)** University of California at Los Angeles

**References:**

1.    Neer CS 2nd, Watson KC, Stanton FJ. Recent experience in  
total shoulder replacement. J Bone Joint Surg Am.  
1982;64(3):319-37.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmushogeschool



2. Rasmussen JV, Brorson S, Hallan G, Dale H, Äärimala V, Mokka J, Jensen SL, Fenstad AM, Salomonsson B. Is it feasible to merge data from national shoulder registries? A new collaboration within the Nordic Arthroplasty Register Association. *J Shoulder Elbow Surg.* 2016 Dec;25(12):369-77.
3. Matsen FA 3rd. Early effectiveness of shoulder arthroplasty for patients who have primary glenohumeral degenerative joint disease. *J Bone Joint Surg Am.* 1996;78:260-4.
4. Khatib O, Onyekwelu I, Yu S, Zuckerman JD. Shoulder arthroplasty in New York State, 1991 to 2010: changing patterns of utilization. *J Shoulder Elbow Surg.* 2015 Oct;24(10):286-91.
5. Day JS, Lau E, Ong KL, Williams GR, Ramsey ML, Kurtz SM. Prevalence and projections of total shoulder and elbow arthroplasty in the United States to 2015. *J Shoulder Elbow Surg.* 2010 Dec;19(8):1115-20.
6. Franklin JL, Barrett WP, Jackins SE, Matsen FA 3rd. Glenoid loosening in total shoulder arthroplasty. Association with rotator cuff deficiency. *J Arthroplasty.* 1988;3:39-46.



- 1  
2  
3 267 7. Sperling JW, Cofield RH, Rowland CM. Neer  
4  
5  
6 268 hemiarthroplasty and Neer total shoulder arthroplasty in patients  
7  
8  
9 269 fifty years old or less. Long-term results. J Bone Joint Surg Am.  
10  
11  
12 270 1998 Apr;80:464-73.  
13  
14  
15 271 8. Torchia ME, Cofield RH, Settergren CR. Total shoulder  
16  
17  
18 272 arthroplasty with the Neer prosthesis: long-term results. J  
19  
20  
21 273 Shoulder Elbow Surg. 1997;6:495-505.  
22  
23  
24 274 9. Wirth MA, Rockwood CA Jr. Complications of total  
25  
26  
27 275 shoulder-replacement arthroplasty. J Bone Joint Surg Am.  
28  
29  
30 276 1996;78:603-16.  
31  
32  
33  
34 277 10. Higgins J, Green S. Cochrane Handbook for Systematic  
35  
36  
37 278 Reviews of Interventions. Version 5. London: Cochrane  
38  
39  
40 279 Collaboration; 2011.  
41  
42  
43 280 11. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ,  
44  
45  
46 281 Johnston RV, Thomas J. Chapter 3: Defining the criteria for  
47  
48  
49 282 including studies and how they will be grouped for the synthesis.  
50  
51  
52 283 In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page  
53  
54  
55 284 MJ, Welch VA (editors). Cochrane Handbook for Systematic  
56  
57  
58  
59  
60

- 285    Reviews of Interventions version 6.0 (updated July 2019).
- 286    Cochrane, 2019.
- 287    12.    Moher D, Shamseer L, Clarke M, Gherzi D, Liberati A,  
288    Petticrew M, et al. Preferred reporting items for systematic review  
289    and meta-analysis protocols (PRISMA-P) 2015 statement. Syst  
290    Rev. 2015 Jan; 4:1.
- 291    13.    Shamseer L, Moher D, Clarke M, Gherzi D, Liberati A,  
292    Petticrew M, et al. Preferred reporting items for systematic review  
293    and meta-analysis protocols (PRISMA-P) 2015: elaboration and  
294    explanation. BMJ. 2015;349.
- 295    14.    Edwards TB, Labriola JE, Stanley RJ, O'Connor DP,  
296    Elkousy HA, Gartsman GM. Radiographic comparison of pegged  
297    and keeled glenoid components using modern cementing  
298    techniques: a prospective randomised study. J Shoulder Elbow  
299    Surg. 2010 Mar;19(2):251-7.
- 300    15.    Kilian CM, Press CM, Smith KM, O'Connor DP, Morris BJ,  
301    Elkousy HA, Gartsman GM, Edwards TB. Radiographic and  
302    clinical comparison of pegged and keeled glenoid components  
303    using modern cementing techniques: midterm results of a

- 304 prospective randomised study. J Shoulder Elbow Surg. 2017  
305 Dec;26(12):2078-2085.
- 306 16. Gartsman GM, Elkousy HA, Warnock KM, Edwards TB,  
307 O'Connor DP. Radiographic comparison of pegged and keeled  
308 glenoid components. J Shoulder Elbow Surg. 2005 May-  
309 Jun;14(3):252-7.
- 310 17. Rahme H, Mattsson P, Wikblad L, Nowak J, Larsson S.  
311 Stability of cemented in-line pegged glenoid compared with  
312 keeled glenoid components in total shoulder arthroplasty. J Bone  
313 Joint Surg Am. 2009 Aug;91(8):1965-72.
- 314 18. Constant CR, Murley AH. A clinical method of functional  
315 assessment of the shoulder. Clin Orthop Relat Res. 1987  
316 Jan;214:160-4.
- 317 19. Michener LA, McClure PW, Sennett BJ. American Shoulder  
318 and Elbow Surgeons Standardized Shoulder Assessment Form,  
319 patient self-report section: reliability, validity, and  
320 responsiveness. J Shoulder Elbow Surg. 2002 Nov-  
321 Dec;11(6):587-94.

- 1  
2  
3 322 20. Amstutz HC, Sew Hoy AL, Clarke IC. UCLA anatomic  
4  
5  
6 323 total shoulder arthroplasty. Clin Orthop Relat Res. 1981 Mar-  
7  
8  
9 324 Apr;155:7-20.
- 10  
11  
12 325 21. McCormack HM, Horne DJ, Sheather S. Clinical  
13  
14  
15 326 applications of visual analogue scales: a critical review. Psychol  
16  
17  
18 327 Med. 1988;18:1007-19.
- 19  
20  
21 328 22. Franklin JL, Barrett WP, Jackins SE, Matsen FA 3rd.  
22  
23  
24 329 Glenoid loosening in total shoulder arthroplasty. Association with  
25  
26  
27 330 rotator cuff deficiency. J Arthroplasty. 1988;3:39-46.
- 28  
29  
30 331 23. Lazarus MD, Jensen KL, Southworth C, Matsen FA 3rd.  
31  
32  
33 332 The radiographic evaluation of keeled and pegged glenoid  
34  
35  
36 333 component insertion. J Bone Joint Surg Am. 2002;84(7):1174-82.
- 37  
38  
39 334 24. Taft C, Karlsson J, Sullivan M. Do SF-36 summary  
40  
41  
42 335 components scores accurately summarize subscale scores? Qual  
43  
44  
45 336 Life Res. 2001;10(5):395-404.
- 46  
47  
48 337 25. Searching for studies.: The Cochrane Collaboration; 2011.
- 49  
50  
51 338 URL:<http://training.cochrane.org/resource/searching-studies>
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 339 26. Cochrane Handbook for Systematic Reviews of  
4  
5  
6 340 Interventions Version 5.1.0 [updated March 2011]. JPT Higgins  
7  
8  
9 341 SG, editor: The Cochrane Collaboration; 2011.  
10  
11  
12  
13 342 27. Mahood Q, Van Eerd D, Irvin E. Searching for grey  
14  
15  
16 343 literature for systematic reviews: challenges and benefits. Res  
17  
18  
19 344 Synth Methods. 2014;5(3):221–34.  
20  
21  
22  
23  
24 345 28. Assessing risk of bias in included studies.: The Cochrane  
25  
26  
27 346 Collaboration; 2011. URL:[http://methods.cochrane.org/bias/](http://methods.cochrane.org/bias/assessing-risk-bias-included-studies)  
28  
29 347 [assessing-risk-bias-included-studies](http://methods.cochrane.org/bias/assessing-risk-bias-included-studies)  
30  
31  
32  
33 348 29. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC.  
34  
35  
36 349 Chapter 8: Assessing risk of bias in a randomized trial. In:  
37  
38  
39 350 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,  
40  
41  
42 351 Welch VA (editors). Cochrane Handbook for Systematic Reviews  
43  
44  
45 352 of Interventions version 6.0.0 [updated July 2019]. Cochrane,  
46  
47  
48 353 2019.  
49  
50  
51  
52 354 30. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A,  
53  
54  
55 355 Hróbjartsson A. Chapter 7: Considering bias and conflicts of  
56  
57  
58 356 interest among the included studies. In: Higgins JPT, Thomas J,  
59  
60

- Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).  
Cochrane Handbook for Systematic Reviews of Interventions  
version 6.0 (updated July 2019). Cochrane, 2019.
31. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz  
R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of  
evidence. *J Clin Epidemiol*. 2011;64(4):401–6.
- 
32. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J,  
et al. GRADE guidelines: 1. Introduction-GRADE evidence  
profiles and summary of findings tables. *J Clin Epidemiol*.  
2011;64(4):383–94.
33. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl  
EA, Sketz N, Guyatt GH. Chapter 14: Completing ‘Summary of  
findings’ tables and grading the certainty of the evidence. In:  
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,  
Welch VA (editors). *Cochrane Handbook for Systematic Reviews  
of Interventions* version 6.0 (updated July 2019). Cochrane, 2019.
34. Boileau P, Avidor C, Krishnan SG, et al. Cemented  
polyethylene versus uncemented metal-backed glenoid

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

375 components in total shoulder arthroplasty: a prospective, double-  
376 blind, randomized study. J Shoulder Elbow Surg. 2002;11:51–9.

377 35. Fox TJ, Cil A, Sperling JW, Sanchez-Sotelo J, Schleck CD,  
378 Cofield RH. Survival of the glenoid component in shoulder  
379 arthroplasty. J Shoulder Elbow Surg. 2009;18: 859-63.

380 36. Walch G, Young AA, Boileau P, Loew M, Gazielly D, Mole  
381 D. Patterns of Loosening of Polyethylene Keeled Glenoid  
382 Components After Shoulder Arthroplasty for Primary  
383 Osteoarthritis. Results of a Multicenter Study with More Than  
384 Five Years of Follow-up. J Bone Joint Surg Am. 2012;94:145-50.

385 37. Boileau P, Moineau G, Morin-Salvo N, Avidor C,  
386 Godenèche A, Lévine C, et al. Metal-backed glenoid implant  
387 with polyethylene insert is not a viable long-term therapeutic  
388 option. J Shoulder Elbow Surg. 2015;24:1534-43.

389 38. Throckmorton TW, Zarkadas PC, Sperling JW, Cofield RH.  
390 Pegged versus keeled glenoid components in total shoulder  
391 arthroplasty. J Shoulder Elbow Surg. 2010;19: 726-33.

392 39. Papadonikolakis A, Matsen FA 3rd. Metal-Backed Glenoid  
393 Components Have a Higher Rate of Failure and Fail by Different  
394 Modes in Comparison with All-Polyethylene Components: A  
395 Systematic Review. J Bone Joint Surg Am. 2014 Jun  
396 18;96(12):1041-7.

### 397 **Consent for publication**

398 Not applicable.

### 399 **Availability of data and materials**

400 The datasets that will be used and/or analysed during the current study will  
401 be available from the corresponding author on reasonable request.

### 402 **Competing interests**

403 The author(s) declare(s) that they have no competing interests.

### 404 **Funding**

405 Unfunded

### 406 **Authors information**

### 407 **Affiliation**

408 Department of Orthopaedics and Traumatology, Universidade Federal de  
409 São Paulo, São Paulo, São Paulo, Brazil.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

410 Renato A. Zan, Fábio T. Matsunaga, Nicola A. Netto, João Carlos Belloti  
411 & Marcel J. S. Tamaoki.  
412 Department of Orthopaedics and Traumatology, Hospital Felício Rocho,  
413 Belo Horizonte, Minas Gerais, Brazil.  
414 Rafael Fuchs Lazarini.

415 **Contributions**

416 RAZ is the guarantor of the review and drafted the manuscript. RAZ, FTM,  
417 JCB and MJST conceptualized the methods. RAZ and RFL contributed for  
418 the development of the eligibility criteria, and the data extraction items.  
419 RAZ, FTM and MJST designed the work. NAN helped with the electronic  
420 search and translation. All authors reviewed several drafts of the  
421 manuscript for critical content and also approved the final protocol.

422 **Acknowledgements**

423 Not applicable.

424 **Corresponding author**

425 Correspondence to Renato A. Zan ([re\\_zan@hotmail.com](mailto:re_zan@hotmail.com) or  
426 [rgan@unifesp.com.br](mailto:rgan@unifesp.com.br)).

**PROSPERO****International prospective register of systematic reviews****Glenoid component in anatomic total shoulder arthroplasty***Marcel Jun Tamaoki, Fábio Matsunaga***Citation**

Marcel Jun Tamaoki, Fábio Matsunaga. Glenoid component in anatomic total shoulder arthroplasty. PROSPERO 2018 CRD42018079537 Available from: [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42018079537](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018079537)

**Review question**

Total shoulder arthroplasty patients above 18 years old, due to osteoarthritis, comparing glenoid components, shoulder function, complications.

**Searches**

"arthroplasty, replacement, shoulder", keeled OR pegged OR metal back [MeSH Terms], from 2006 to 2017.

Our search will be carried in the Cochrane Library, PubMed, Excerpta Medica Database (EMBASE), and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS).

In addition, ongoing and recently completed clinical trial protocols will be searched in the ISRCTN Registry ([www.isrctn.com](http://www.isrctn.com)), International Clinical Trials Registry Platform, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, LILACS, and Plataforma Brasil.

There will be no restrictions to language or publication status.

**Types of study to be included**

Clinical randomized trials or quasi randomized.

**Condition or domain being studied**

Total shoulder arthroplasty due to arthritis, fracture sequelae, inflammatory, analyzing the glenoid component (keeled, pegged, metal back), which one is better?

**Participants/population**

Adults above 18 years old.

**Intervention(s), exposure(s)**

Total shoulder arthroplasty with metal back glenoid component.

**Comparator(s)/control**

Total shoulder arthroplasty with polyethylene glenoid component, keeled or pegged.

**Context****Main outcome(s)**

Shoulder function and complications.

**Timing and effect measures**

6 months and 1 year follow up.

**Additional outcome(s)**

X-rays and quality of life.

**Timing and effect measures**

6 months and 1 year follow up.

**Data extraction (selection and coding)**

Electronic search from PubMed, Google Academic, Embase and MEDLINE. 2 researchers, discrepancies will

## PROSPERO

### International prospective register of systematic reviews

be resolved by a third researcher.

#### Risk of bias (quality) assessment

2 researchers will access independently, without masking of the source or authorship of trial reports, discrepancies will be resolved by a third researcher.

#### Strategy for data synthesis

Pool results of comparable groups of trials using the fixed-effect model and 95% confidence intervals.

#### Analysis of subgroups or subsets

Perform subgroup analyses in order to explore effect size differences in relation to the glenoid type.

#### Contact details for further information

Renato Zan

re\_zan@hotmail.com

#### Organisational affiliation of the review

Unifesp

[www.unifesp.br](http://www.unifesp.br)

#### Review team members and their organisational affiliations

Dr Marcel Jun Tamaoki. Unifesp

Dr Fábio Matsunaga. Unifesp

#### Anticipated or actual start date

07 November 2016

#### Anticipated completion date

03 June 2019

#### Funding sources/sponsors

Unifesp

#### Conflicts of interest

#### Language

(there is not an English language summary)

#### Country

Brazil

#### Stage of review

Review\_Ongoing

#### Subject index terms status

Subject indexing assigned by CRD

#### Subject index terms

Arthroplasty, Replacement, Shoulder; Humans; Scapula; Shoulder

#### Date of registration in PROSPERO

11 January 2018

#### Date of publication of this version

11 January 2018

#### Details of any existing review of the same topic by the same authors

#### Stage of review at time of this submission

**PROSPERO****International prospective register of systematic reviews**

Preliminary searches	Yes	No
Piloting of the study selection process	Yes	No
Formal screening of search results against eligibility criteria	Yes	No
Data extraction	Yes	No
Risk of bias (quality) assessment	Yes	No
Data analysis	Yes	No

**Versions**

11 January 2018

**PROSPERO**

This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites.

**Glenoid Failure after Total Shoulder Arthroplasty, cemented all-polyethylene versus metal-backed: A Systematic Review Protocol**

Databases:

- Medline
- EMBASE

Date range:

- All dates included.

Renato Aroca Zan, Rafael Fuchs Lazarini, Fábio Teruo Matsunaga, Nicola Archetti Netto, João Carlos Belloti & Marcel Jun Sugawara Tamaoki.

**Full Search Strategy**

Languages:• All languages included (where applicable, attempts at translation will be conducted).

Population:• All populations included (to be specified in inclusion/exclusion criteria during screening).

Study Type:• All study types included (to be specified in inclusion/exclusion criteria during screening).

Medline (Ovid) Legend:

(((((("arthroplasty, replacement, shoulder"[MeSH Terms] OR ("arthroplasty"[All Fields] AND "replacement"[All Fields] AND "shoulder"[All Fields]) OR "shoulder replacement arthroplasty"[All Fields] OR ("total"[All Fields] AND "shoulder"[All Fields] AND "arthroplasty"[All Fields]) OR "total shoulder arthroplasty"[All Fields]) AND glenoid[All Fields]) AND loosening[All Fields]) OR keeled[All Fields]) OR pegged[All Fields]) OR metal-backed[All Fields]) AND radiolucency[All Fields]AND

EMBASE (Ovid) Legend:

#1('total shoulder arthroplasty':ti,ab,kw AND 'glenoid cavity':ti,ab,kw AND 'prosthesis loosening':ti,ab,kw OR 'glenoid baseplate' OR 'glenoid component of shoulder prosthesis' OR polyethylene) AND radiolucency glenoid loosening2020-04-272020-04-27105

Sources

MEDLINE

Embase

Search ('total shoulder arthroplasty': ti,ab,kw AND 'glenoid cavity':ti,ab,kw AND 'prosthesis loosening':ti,ab,kw OR 'glenoid baseplate' OR 'glenoid component of shoulder prosthesis' OR polyethylene) AND radiolucency

In Fields total shoulder arthroplasty in Title total shoulder arthroplasty in Abstract total shoulder arthroplasty in Author keyword glenoid cavity in Title glenoid cavity in

Abstract glenoid cavity in Author keyword prosthesis loosening in Title prosthesis  
loosening in Abstract prosthesis loosening in Author keyword

For peer review only

PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1-3
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	46
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4-8, 408-414
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	416-421
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	67-85
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to	<input checked="" type="checkbox"/>	<input type="checkbox"/>	80-85



Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
		participants, interventions, comparators, and outcomes (PICO)			
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	88-93, 99-103
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	123-129
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	130-133
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	135-137
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	138-142
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	135-154
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	144-154
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	104-121
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	155-164
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	185-187
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	166-172
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	193-194
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	189-198
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	189-194



Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	195-198

For peer review only

# BMJ Open

## Glenoid failure after total shoulder arthroplasty with cemented all-polyethylene versus metal-backed implants: a systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043449.R1
Article Type:	Protocol
Date Submitted by the Author:	24-Oct-2020
Complete List of Authors:	Zan, Renato Aroca; Universidade Federal de Sao Paulo, Orthopedics and Traumatology - Division of Hand surgery and Upper Limb Lazarini, Rafael; Hospital Felicio Rocho, Department of Orthopaedics and Traumatology Matsunaga, Fabio; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb Netto, Nicola; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb Belloti, João ; Federal University of São Paulo (UNIFESP/EPM), Orthopedics and Traumatology - Division of Hand Surgery and Upper Limb; Universidade Federal de Sao Paulo Escola Paulista de Medicina, Tamaoki, Marcel Jun; Universidade Federal de Sao Paulo, Orthopaedics
<b>Primary Subject Heading</b>:	Evidence based practice
Secondary Subject Heading:	Surgery
Keywords:	Shoulder < ORTHOPAEDIC & TRAUMA SURGERY, STATISTICS & RESEARCH METHODS, Adult orthopaedics < ORTHOPAEDIC & TRAUMA SURGERY, Elbow & shoulder < ORTHOPAEDIC & TRAUMA SURGERY, RADIOLOGY & IMAGING

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# **Glenoid failure after total shoulder arthroplasty with cemented all-polyethylene versus metal-backed implants: a systematic review protocol**

Renato Aroca Zan<sup>1</sup>, Rafael Fuchs Lazarini<sup>2</sup>, Fabio Teruo Matsunaga<sup>1</sup>, Nicola Archetti Netto<sup>1</sup>, João Carlos Belloti<sup>1</sup>, Marcel Jun Sugawara Tamaoki<sup>1</sup>

<sup>1</sup>Department of Orthopaedics and Traumatology, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.

<sup>2</sup>Department of Orthopaedics and Traumatology, Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil.

## **Corresponding author**

Renato A. Zan

Department of Orthopaedics and Traumatology, Universidade Federal de São Paulo

São Paulo, São Paulo, Brazil. R. Napoleão de Barros, 715 - Vila Clementino

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002

Email: [re\\_zan@hotmail.com](mailto:re_zan@hotmail.com)

Word count: 4,280

## **Abstract**

## **Introduction**

Anatomical Total Shoulder Arthroplasty (TSA) is an effective treatment adopted for patients with glenohumeral osteoarthritis. The glenoid component failure is the main risk that occurs in this therapeutic choice; however, doubts remain regarding the selection of the best implant for avoiding complication. This systematic review aims to

evaluate the glenoid component in TSA by comparing the complications of different types of implants.

**Methods and analysis**

A systematic review of randomised clinical trials or quasi-randomised trials will be performed by applying the Preferred Reporting Items for Systematic Review and Meta-Analysis protocols and comparing polyethylene (keeled and pegged) versus metal-backed implants in adult patients with glenohumeral osteoarthritis. Our search strategy will be performed using MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, and Web of Science. Data management and extraction will be performed using a data withdrawal form and by analysing study method characteristics, participant characteristics, intervention characteristics, results, and methodological domains. The database search will be performed by February 2021. The Grading of Recommendations Assessment, Development and Evaluation will be used for assessing the quality of evidence of each study selected; however, some critical and important outcomes were determined such as the shoulder function through functional scores (Constant-Murley and American Shoulder and Elbow Surgeons), complications represented by pain (visual analogue scale), surgical revision, radiograph radiolucency, and loosening. The confidence in estimated effects for these outcomes will be applied as the overall confidence. The outcomes will be defined as early or late, according to the postoperative follow-up of less than or greater than one year, respectively, for complications and radiographs. For the shoulder function, follow-ups will be divided into 6, 12, and 24 months. Heterogeneity is expected in systematic reviews; therefore, the selection of outcomes, as well as the sample size, and specific statistical analysis can lead to meta-analysis; however, if it fails, narrative evidence synthesis will be conducted. Other analyses such as descriptive, subgroup, and sensitivity analyses will

be performed whenever possible. This systematic review will, therefore, provide evidence concerning the best clinical practice for avoiding complications.

### **Ethics and dissemination**

This study has been approved by the institutional review board of Universidade Federal de São Paulo (protocols 0725/2017, 2.157.415, and 70473017.5.0000.5505), and the findings will be disseminated through peer-reviewed publication and conference presentations.

### **Systematic review registration**

PROSPERO, CRD 42018079537.

### **Strengths and limitations of this study**

- This systematic review will be conducted in response to a gap in the evidence regarding an increasing number of shoulder surgical procedures performed for treating shoulder osteoarthritis.
- This review will include only randomised and non-randomised controlled trials for assessing all relevant available evidence regarding the types of glenoid implants for total shoulder arthroplasties for shoulder osteoarthritis.
- A comprehensive search will be performed across several databases with no restrictions for language, date, and status of publication.
- We expect difficulty in finding trials with adequate sample size, standardisation of the functional scores, follow-up pattern, and methods of the results, indicating a possible limitation in our revision.
- All authors of this review have expertise in methodology in systematic reviews as well as experience in orthopaedic surgical procedures that will ensure relevance to applicability and practice.

**Introduction**

Osteoarthritis (OA) of the glenohumeral joint is a common clinical condition that affects adult population between 60 and 80 years old.[1, 2] Total Shoulder Arthroplasty (TSA) has been proven to be effective for treating this condition.[3] Utilisation of TSA increased between 300%–400% for the last two decades (1990–2010), varying from 13,000–42,000 approximately, with an annual variation of 10.6%.[4, 5] Approximately 24% of complications of TSA were related to glenoid implant, and 28.5% of those required surgical revision owing to loosening of the implant. Metal-backed glenoid component (MB) thickness is approximately 7 mm (4 mm for the polyethylene insert and 3 mm for the metal tray); two screws provided initial stability, and a porous back surface provided bone ingrowth; [6] in contrast, polyethylene component (PE) thickness is approximately 3–4 mm; [7] it is fixed across the glenoid surface through pegs or keel requiring cement and its elasticity modulus is 0.5 GPa, which is closest to cancellous (0.4 GPa) and cortical (2.0 GPa) bones and far from metal (cobalt/chrome (200 GPa) and titanium (112 GPa)).[7] Loosening of the glenoid implant is the main cause of failure, followed by pain and decrease in the range of motion after a TSA. [8, 9, 10, 11] This complication compromises the function of the joint and reoperation might be needed.

This systematic review aims to evaluate the glenoid component in TSA by comparing the complications of different types of implants, either with MB or PE components (keeled or pegged), considering the function of the shoulder, complications (persistence or worsening of pain and failure of the surgery with regard to the implant loosening in the glenohumeral joint leading to a revision surgery), and radiograph radiolucency.

**Methods and analysis**

**Types of studies and inclusion criteria:**

This systematic review will follow the recommendations proposed by the Cochrane Handbook of Interventions Reviews[12, 13] and PRISMA protocols[14, 15]. Our study will include only randomised or quasi-randomised controlled clinical trials, comparing MB glenoid designs and PE designs (keeled or pegged) for TSA; other studies such as experimental, cadaveric, cohort, observational, case report, and case control will be excluded. Small samples of <five participants will not be eligible. We expect difficulty in finding trials with adequate sample size.

### **Ethics approval and dissemination:**

The study has been approved by the institutional review board of Universidade Federal de São Paulo (protocol 0725/2017, 2.157.415, and 70473017.5.0000.5505) (document attached).

### **Types of participants (inclusion and exclusion criteria)**

Eligible articles with adults patients (>18 years old) who underwent TSA, with cemented pegs or keel PE or MB, owing to idiopathic or inflammatory OA[16, 17, 18, 19] will be included in this study. The following exclusion criteria will be adopted: Patients with previous surgery, neurological diseases (Charcot's arthropathy, Parkinson's disease, etc.), revision surgeries of arthroplasty, reverse total arthroplasty, and studies assessing other types of glenoid implants or even mixed arthroplasties (i.e., use of bone graft).

### **Primary outcomes (critical)**

Shoulder function will be assessed with six, 12, and 24 months of postoperative follow-ups, with two validated scores, Constant-Murley (CM)[20] and American Shoulder and Elbow Surgeons (ASES)[21]; the analysis is made on the following aspects: activity level, range of motion, arm positioning, usage of pain killers, and work. Complications such as persistence or worsening of pain (visual analogue scale (VAS))[22] and



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

121 loosening or breakage of implanted materials can lead to a surgical revision. These  
122 outcomes will be assessed as early or late, according to the postoperative follow-up of  
123 less than or greater than one year.

124 **Secondary outcomes (important)**

125 Radiolucency will be assessed by the occurrence of radiographic lines between the  
126 glenoid implant/cement and the native bone, indicating the loosening of the implant.  
127 Lazarus classification for keeled components and Franklin classification for pegged  
128 components will be used for assessing radiolucency concerning all-polyethylene  
129 components.[23, 24] This outcome will be assessed as early or late, according to the  
130 postoperative follow-up of less than or greater than one year.

131 **Search methods and strategy**

132 The electronic search will be performed in February 2021 using MEDLINE (PubMed),  
133 Cochrane Central Register of Controlled Trials,[25, 26] EMBASE, Web of Science,  
134 International Clinical Trials Registry Platform, ClinicalTrials.gov, and Literatura  
135 Latino-Americana e do Caribe em Ciências da Saúde (LILACS for randomised or  
136 quasi-randomised controlled trials). The grey literature will also be searched using  
137 Google Scholar, OpenGrey, and GreyNet.[27] A medical librarian expert and a  
138 discussion group, will conduct effective search strategy.

139 The following terms will be used in different combinations and combinations for our  
140 search: ((((((“arthroplasty, replacement, shoulder”[MeSH Terms] OR  
141 (“arthroplasty”[All Fields] AND “replacement”[All Fields] AND “shoulder”[All  
142 Fields]) OR “shoulder replacement arthroplasty”[All Fields] OR (“total”[All Fields]  
143 AND “shoulder”[All Fields] AND “arthroplasty”[All Fields]) OR “total shoulder  
144 arthroplasty”[All Fields]) AND glenoid[All Fields]) AND loosening[All Fields]) OR  
145 keeled[All Fields]) OR pegged[All Fields]) OR metal-backed[All Fields]) AND

radiolucency[All Fields]. There will be no restriction on language or publication status.

Full search strategies for the main databases are provided in appendix 1.

### **Data collection and analysis**

Two independent reviewers will access the selected studies and the extracted data from these studies using EndNote X9 (Copyright Clarivate Analytics, 22 Thomson Place, 36T3 Boston, MA 02210, U.S.), to facilitate collaboration among them during the selection process.

Two authors will independently select and analyse the eligible studies for this systematic review through the title and abstract using the following criteria: 1) randomised clinical trials or quasi-randomised trials, 2) TSA with cemented glenoid PE or MB, 3) TSA loosening after PE or MB. Selected studies will be entirely reviewed for determining their eligibility, and any disagreement will be solved through discussion and, when necessary, will be judged by a third author in an attempt to resolve a possible conflict.

Based on the population, intervention, comparisons, and outcomes,[28, 29] the results will be established for each outcome, the magnitude of the effects, and the assessment of the quality of evidence (QE), besides the five reasons (risk of bias, imprecision, inconsistency, indirectness, and risk of publication bias) that can lower the confidence in those estimated effects, downgrading the QE.

### **Data extraction and handling**

Data extraction will be performed by two reviewers; data will be extracted using an appropriate customised extraction form (Microsoft Access/Excel, Excel Version 16.34.2020), based on 1) methodological characteristics, including design and duration, whether the protocol was published prior to the recruitment of the patients, possible funding sources, and study registration; 2) characteristics of the participants including

location, number of recruits, their evaluation, inclusion and exclusion criteria, age, and classification relevant to the disease addressed; 3) characteristics of the intervention such as duration, surgery type, and complications; 4) results through time and loss of follow-up; and 5) methodological domains and risk of bias.[29, 30]

The extracted data will be further classified according to the time of follow-up as early and late, establishing one year as the cut off for this division.

**Assessment of risk of bias**

Two authors will independently evaluate various aspects of the methodological quality of the included studies using GRADE (www.gradepr.org)[31] for assessing limitations in study design and execution, similar to a modified version of the Cochrane Bone Joint and Muscle Trauma Group tool form.[32] Some items will be considered: random sequence generation, allocation concealment, participant blinding, intention-to-treat analysis properly applied, loss of follow-up, outcome assessment blinding, quality criteria such as trials that stopped early for benefit and when there are cross-over designs, selective reporting, and potential influence of incomplete outcome data for each trial, will also be performed. After judgment and classification, the QE for each outcome will generate three levels of risk of bias: high, uncertain, and low, and it can be rated by the GRADE approach depending on the “seriousness” of bias.[33, 34] Disagreements will be solved by the analysis of a third reviewer after further analysis.[31, 32]

**Measures of treatment effect**

The resulting dichotomous data will be analysed with a relative risk (RR) and 95% confidence interval (CI). When appropriate, the estimated effects will be expressed as numbers that need treatment (NNTs) measuring the complications of the two types of

glenoid implants in the population of TSA. Data on continuous outcomes will be expressed as an average difference of 95% (CI). The results will be grouped with the mean difference (MD) if two or more trials reveal results from the same valid instrument of evolution (with the same units of measurement). If primary studies measure the same outcomes such as shoulder function through validated scores, complications, or radiograph using different instruments (as well as different units of measurement), odds ratio will be transformed into standard mean difference (SMD) and effect size. The Cochrane Review Manager (Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) will be used for statistical analyses, combining SMD using inverse variance method. Selective publication of studies can lead to a false estimated effect known as “fill drawer problem”. Small numbers of patients and studies funded by industry are also factors that negatively influence publication bias, which can be evaluated using funnel plots; less publications bias was detected when studies were distributed around the best estimate of effect (hazard ratio).[34, 35, 36, 37]

## **Missing data**

An intention-to-treat analysis will be performed to include all randomised participants of any intervention. Authors of the selected trials will be contacted regarding insufficient information according to the estimated effects as well as the number of participants, uncertainty in measurements (standard deviation or error), or number of events. An analysis will be performed independently of the lost data according to the worst-case and best-case scenarios.[35]

## **Descriptive analysis**

All studies will be described in detail with a valid tool because of heterogeneous information, varied objectives, inclusion criteria, data collection methods, as well as participants demographic characteristics, and each outcome.

**Subgroup analysis and heterogeneity investigation and analysis**

Subgroups will be analysed to explore the difference in the side effect related to the type of glenoid implant selected.[35] The heterogeneity of estimated effects between the included studies will be evaluated using the following topics:

- 1) Split subgroups for allowing comparisons (PE × MB, keel PE × peg PE) if trials are similar,
- 2) Separate factors that introduce heterogeneity using summary plot,
- 3) Determine relative effects,
- 4) Visual inspection using Forestal plot and statistical Higgins I<sup>2</sup> test (significant > 50%).

**Data synthesis**

The results of comparative tests will be grouped using the random-effect model and a 95% CI because of different true estimated effects between the selected studies, diversity in population, or methodological characteristics. Despite study similarities, studies cannot be assumed to be identical. However, the variable model will be used when there is a diversity in clinical or methodological characteristics.

**Sensitivity analysis**

The effects of concealment allocation, studies at risk of bias, missing data, time bias, sub-populations, different pre-diagnoses, and other kind of implants or surgical techniques will be investigated. Such articles will be excluded so that the quality of our primary analysis is not compromised.[35]

**Confidence in cumulative evidence**

GRADE ([www.gradepro.org](http://www.gradepro.org)) will be applied to describe and rate the QE and the strength of recommendations, classifying them as *high*, *moderate*, *low*, and *very low*[38, 39, 40] according to the study design, ranging from the randomised trials (high QE) to observational studies (low QE). The five categories mentioned before (risk of bias, inconsistency, indirectness, imprecision, and publication bias) can lower the GRADE approach; however, large effects, dose-response relationship, and all plausible residual confounders or biases (would reduce a demonstrated effect or suggest a spurious effect if no effect was observed) can upgrade the QE.[34]

Some critical and important outcomes for the GRADE approach were determined: shoulder function through functional scores (CM and ASES), complications represented by pain (VAS), surgical revision, radiograph radiolucency, and loosening.[41] These outcomes will be assessed individually, and individual recommendation will be provided.

Following this protocol publication, electronic search will be performed and the selected trials will be analysed. Once we get the results, we intend to publish this manuscript. Our intention is to have the manuscript ready by the end of 2021. We expect to observe an increasing rate of TSA in the adult population; therefore, complications also assume an increasingly important role in this particular treatment.

The glenoid component is the main site of these complications in terms of pain, limiting the range of motion and worsening the quality of life. These findings are correlated with loosening or even implant breakage.[42] There is some evidences that cemented all-PE glenoid implant has a better loosening rate than the metal-backed design, but in terms of radiolucency, this statement is reversed.[6, 43, 44, 45]

Currently, there are several types of glenoid implants in both PE and MB designs; however, there is a lack of systematic reviews based on a literature search. Particularly,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

only one study was found, including trials with a low level of evidence such as nonrandomised and case series.[46] Further evaluation on this subject with better methodological quality should be performed for covering functional, clinical, and radiographic outcomes as well as complications.

We expect difficulty in finding trials with adequate sample size, standardisation of the functional scores, follow-up pattern, and methods of the results, indicating a possible limitation in our revision. Our study will serve as a guide for future trials with better methodological quality.

**Ethics approval and dissemination**

This study has been approved by the institutional review board of Universidade Federal de São Paulo (protocol 0725/2017, 2.157.415, and 70473017.5.0000.5505) (document attached).

**References**

1. Neer CS 2nd, Watson KC, Stanton FJ. Recent experience in total shoulder replacement. *J Bone Joint Surg Am* 1982;64:319–37.
2. Rasmussen JV, Brorson S, Hallan G, et al. Is it feasible to merge data from national shoulder registries? A new collaboration within the Nordic Arthroplasty Register Association. *J Shoulder Elbow Surg* 2016;25:369–77.
3. Matsen FA 3rd. Early effectiveness of shoulder arthroplasty for patients who have primary glenohumeral degenerative joint disease. *J Bone Joint Surg Am* 1996;78:260–4.
4. Khatib O, Onyekwelu I, Yu S, et al. Shoulder arthroplasty in New York State, 1991 to 2010: changing patterns of utilization. *J Shoulder Elbow Surg* 2015;24:286–91.



- 291 5. Day JS, Lau E, Ong KL, et al. Prevalence and projections of total shoulder and  
292 elbow arthroplasty in the United States to 2015. *J Shoulder Elbow Surg* 2010;19:1115–  
293 20.
- 294 6. Boileau P, Moineau G, Morin-Salvo N, et al. Metal-backed glenoid implant with  
295 polyethylene insert is not a viable long-term therapeutic option. *J Shoulder Elbow Surg*  
296 2015;24:1534–43.
- 
- 297 7. Matsen FA 3rd, Lippitt SB, Rockwood CA Jr, et al. Chapter 16 Glenohumeral  
298 arthritis and its management. In: Rockwood CA Jr, Matsen FA 3rd, Wirth MA, et al.,  
299 eds. *Rockwood and Matsen's The Shoulder*. 5th ed. Philadelphia, PA:  
300 Saunders/Elsevier 2016:831–1042.
- 301 8. Franklin JL, Barrett WP, Jackins SE, et al. Glenoid loosening in total shoulder  
302 arthroplasty. Association with rotator cuff deficiency. *J Arthroplasty* 1988;3:39–46.
- 303 9. Sperling JW, Cofield RH, Rowland CM. Neer hemiarthroplasty and Neer total  
304 shoulder arthroplasty in patients fifty years old or less. Long-term results. *J Bone Joint*  
305 *Surg Am* 1998;80:464–73.
- 306 10. Torchia ME, Cofield RH, Settegren CR. Total shoulder arthroplasty with the  
307 Neer prosthesis: long-term results. *J Shoulder Elbow Surg* 1997;6:495–505.
- 308 11. Wirth MA, Rockwood CA Jr. Complications of total shoulder-replacement  
309 arthroplasty. *J Bone Joint Surg Am* 1996;78:603–16.
- 
- 310 12. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of*  
311 *Interventions*. Version 5. London: Cochrane Collaboration 2011.
- 312 13. McKenzie JE, Brennan SE, Ryan RE, et al. Chapter 3: Defining the criteria for  
313 including studies and how they will be grouped for the synthesis. In: Higgins JPT,



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

314 Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of  
315 Interventions version 6.0 (updated July 2019). Cochrane 2019.

316 14. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
317 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

318 15. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic  
319 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.  
320 *BMJ* 2015;350:g7647.

321 16. Edwards TB, Labriola JE, Stanley RJ, et al. Radiographic comparison of pegged  
322 and keeled glenoid components using modern cementing techniques: a prospective  
323 randomised study. *J Shoulder Elbow Surg* 2010;19:251–7.

324 17. Kilian CM, Press CM, Smith KM, et al. Radiographic and clinical comparison of  
325 pegged and keeled glenoid components using modern cementing techniques: midterm  
326 results of a prospective randomised study. *J Shoulder Elbow Surg* 2017;26:2078–85.

327 18. Gartsman GM, Elkousy HA, Warnock KM, et al. Radiographic comparison of  
328 pegged and keeled glenoid components. *J Shoulder Elbow Surg* 2005;14:252–7.

329 19. Rahme H, Mattsson P, Wikblad L, et al. Stability of cemented in-line pegged  
330 glenoid compared with keeled glenoid components in total shoulder arthroplasty. *J*  
331 *Bone Joint Surg Am* 2009;91:1965–72.

332 20. Constant CR, Murley AH. A clinical method of functional assessment of the  
333 shoulder. *Clin Orthop Relat Res* 1987;214:160–4.

334 21. Michener LA, McClure PW, Sennett BJ. American Shoulder and Elbow  
335 Surgeons Standardized Shoulder Assessment Form, patient self-report section:  
336 reliability, validity, and responsiveness. *J Shoulder Elbow Surg* 2002;11:587–94.

22. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. *Psychol Med* 1988;18:1007–19.
23. Lazarus MD, Jensen KL, Southworth C, et al. The radiographic evaluation of keeled and pegged glenoid component insertion. *J Bone Joint Surg Am* 2002;84:1174–82.
24. Franklin JL, Barrett WP, Jackins SE, et al. Glenoid loosening in total shoulder arthroplasty. Association with rotator cuff deficiency. *J Arthroplasty* 1988;3:39–46.
25. Searching for studies (august 2020): The Cochrane Collaboration; 2011. URL:<http://training.cochrane.org/resource/searching-studies>
26. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. JPT Higgins SG, eds. The Cochrane Collaboration 2011.
27. Mahood Q, Van Eerd D, Irvin E. Searching for grey literature for systematic reviews: challenges and benefits. *Res Synth Methods* 2014;5:221–34.
28. Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. *BMC Med Inform Decis Mak* 2007;7:16.
- 
29. Li T, Higgins JPT, Deeks JJ, eds. Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020.
30. Munn Z, Tufanaru C, Aromataris E. JBI's systematic reviews: data extraction and synthesis. *Am J Nurs* 2014;114:49–54.
-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

358 31. Higgins JPT, Savović J, Page MJ, et al. Chapter 8: Assessing risk of bias in a  
359 randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane  
360 Handbook for Systematic Reviews of Interventions version 6.0 0 [updated July 2019].  
361 Cochrane 2019.

362 32. Assessing risk of bias in included studies (august 2020): The Cochrane  
363 Collaboration; 2011. URL:[http://methods.cochrane.org/bias/assessing-risk-bias-](http://methods.cochrane.org/bias/assessing-risk-bias-included-studies)  
364 [included-studies](http://methods.cochrane.org/bias/assessing-risk-bias-included-studies)

365 33. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality  
366 of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011;64:407–15.

367 34. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings  
368 using other methods. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane  
369 Handbook for Systematic Reviews of Interventions version 6.1 (updated September  
370 2020). Cochrane 2020.

371 35. Deeks JJ, Higgins JPT, Altman DG, eds. Chapter 10: Analysing data and  
372 undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane  
373 Handbook for Systematic Reviews of Interventions version 6.1 (updated September  
374 2020). Cochrane 2020.

375 36. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing  
376 summary of findings tables and evidence profiles-continuous outcomes. *J Clin*  
377 *Epidemiol* 2013;66:173–83.

378 37. Boutron I, Page MJ, Higgins JPT, et al. Chapter 7: Considering bias and  
379 conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

- et al., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019.
38. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401–6.
39. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
40. Schünemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019.
41. Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol* 2013;66:151–7.
42. Boileau P, Avidor C, Krishnan SG, et al. Cemented polyethylene versus uncemented metal-backed glenoid components in total shoulder arthroplasty: a prospective, double-blind, randomized study. *J Shoulder Elbow Surg* 2002;11:51–9.
43. Fox TJ, Cil A, Sperling JW, et al. Survival of the glenoid component in shoulder arthroplasty. *J Shoulder Elbow Surg* 2009;18:859–63.
44. Walch G, Young AA, Boileau P, et al. Patterns of Loosening of Polyethylene Keeled Glenoid Components After Shoulder Arthroplasty for Primary Osteoarthritis.

1  
2  
3 401 Results of a Multicenter Study with More Than Five Years of Follow-up. *J Bone Joint*  
4  
5 402 *Surg Am* 2012;94:145–50.  
6  
7  
8 403 45. Throckmorton TW, Zarkadas PC, Sperling JW, et al. Pegged versus keeled  
9  
10 404 glenoid components in total shoulder arthroplasty. *J Shoulder Elbow Surg*  
11  
12 405 2010;19:726–33.  
13  
14  
15  
16 406 46. Papadonikolakis A, Matsen FA 3rd. Metal-backed Glenoid Components Have a  
17  
18 407 Higher Rate of Failure and Fail by Different Modes in Comparison with All-  
19  
20 408 Polyethylene Components: A Systematic Review. *J Bone Joint Surg Am* 2014;96:1041–  
21  
22 409 7.

---

27 410 **Patient and public involvement**  
28  
29 411 No patient was involved. It is a secondary study.  
30  
31 412 **Consent for publication**  
32  
33 413 Not applicable.  
34  
35 414 **Availability of data and materials**  
36  
37 415 The datasets that will be used and/or analysed during the current study will  
38  
39 416 be available from the corresponding author upon reasonable request.  
40  
41 417 **Competing interests**  
42  
43 418 The authors declare that they have no competing interests.  
44  
45 419 **Funding**  
46  
47 420 Unfunded  
48  
49 421 **Contributions**  
50  
51 422 RAZ is the guarantor of the review and drafted the manuscript. RAZ, FTM, JCB,  
52  
53 423 and MJST conceptualized the methods. RAZ and RFL contributed to the  
54  
55 424 development of the eligibility criteria and data extraction items. RAZ, FTM, and  
56  
57  
58  
59  
60

425 MJST designed the work. NAN helped with the electronic search and translation.

426 All authors reviewed several drafts of the manuscript for critical content and

427 approved the final protocol.

428 **Acknowledgements**

429 Not applicable.

---

For peer review only

**Glenoid failure after total shoulder arthroplasty with cemented all-polyethylene versus metal-backed implants: a systematic review protocol**

Databases:

- Medline
- EMBASE

Date range:

- All dates included.

Renato Aroca Zan, Rafael Fuchs Lazarini, Fábio Teruo Matsunaga, Nicola Archetti Netto, João Carlos Belloti & Marcel Jun Sugawara Tamaoki.

Full Search Strategy

Languages:• All languages included (where applicable, attempts at translation will be conducted).

Population:• All populations included (to be specified in inclusion/exclusion criteria during screening).

Study Type:• All study types included (to be specified in inclusion/exclusion criteria during screening).

Medline (Ovid) Legend:

(((((("arthroplasty, replacement, shoulder"[MeSH Terms] OR ("arthroplasty"[All Fields] AND "replacement"[All Fields] AND "shoulder"[All Fields]) OR "shoulder replacement arthroplasty"[All Fields] OR ("total"[All Fields] AND "shoulder"[All Fields] AND "arthroplasty"[All Fields]) OR "total shoulder arthroplasty"[All Fields]) AND glenoid[All Fields]) AND loosening[All Fields]) OR keeled[All Fields]) OR pegged[All Fields]) OR metal-backed[All Fields]) AND radiolucency[All Fields]AND

EMBASE (Ovid) Legend:

#1('total shoulder arthroplasty':ti,ab,kw AND 'glenoid cavity':ti,ab,kw AND 'prosthesis loosening':ti,ab,kw OR 'glenoid baseplate' OR 'glenoid component of shoulder prosthesis' OR polyethylene) AND radiolucency glenoid loosening2020-04-272020-04-27105

Sources

MEDLINE

Embase

Search ('total shoulder arthroplasty': ti,ab,kw AND 'glenoid cavity':ti,ab,kw AND 'prosthesis loosening':ti,ab,kw OR 'glenoid baseplate' OR 'glenoid component of shoulder prosthesis' OR polyethylene) AND radiolucency

In Fields total shoulder arthroplasty in Title total shoulder arthroplasty in Abstract total shoulder arthroplasty in Author keyword glenoid cavity in Title glenoid cavity in

Abstract glenoid cavity in Author keyword prosthesis loosening in Title prosthesis  
loosening in Abstract prosthesis loosening in Author keyword

For peer review only



PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted – Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1-3
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	46
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4-8, 408-414
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	416-421
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	67-85
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to	<input checked="" type="checkbox"/>	<input type="checkbox"/>	80-85

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
		participants, interventions, comparators, and outcomes (PICO)			
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	88-93, 99-103
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	123-129
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	130-133
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	135-137
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	138-142
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	135-154
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	144-154
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	104-121
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	155-164
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	185-187
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	166-172
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	193-194
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	189-198
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	189-194

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	195-198

For peer review only